What is the primary purpose of this 10-Q filing?

The primary purpose of this 10-Q filing is to provide investors and the public with a quarterly update on Bristol Myers Squibb Co.'s financial performance and position. It includes unaudited financial statements and management's discussion of results for the period ending March 30, 1997.

Where can I find the detailed financial results for BMY for this period?

The detailed financial results, including the income statement, balance sheet, and cash flow statement, would be contained within the full 10-Q document itself, which is not fully provided here. Investors need to access the complete filing through the SEC's EDGAR database or other financial data providers.

What kind of information should I look for in the full 10-Q to assess BMY's performance?

Investors should look for key financial metrics such as revenue growth (overall and by product segment), profitability margins (gross, operating, net), earnings per share (EPS), cash flow generation from operations, and any significant changes in the company's debt or equity structure. It's also important to review the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into business trends and risks.

Are there any specific risks or opportunities mentioned in this filing excerpt?

The provided excerpt is a directory listing and does not contain any specific narrative regarding risks, opportunities, or business developments. A thorough review of the full 10-Q document, particularly the risk factors and management discussion sections, would be necessary to identify any such details.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY1997

Summary

Bristol Myers Squibb Co. (BMY) filed its quarterly report for the period ending March 30, 1997. This filing provides a snapshot of the company's financial performance and position during the first quarter of fiscal year 1997. While the provided text does not contain detailed financial statements or operational highlights, investors should review the full 10-Q document for specifics on revenue, profitability, cash flow, and any significant business developments, such as product launches, regulatory approvals, or strategic partnerships. The filing is essential for understanding the company's ongoing trajectory and its ability to generate value for shareholders in a dynamic pharmaceutical market.

Key Highlights

1The filing is a 10-Q report for Bristol Myers Squibb Co. (BMY) covering the period ending March 30, 1997.
2The report was filed on May 15, 1997.
3This document provides periodic financial information for investors.
4Investors should consult the full filing for detailed financial statements and management discussion.
5Key areas to examine in the full report include revenue, net income, and balance sheet items.
6Understanding the financial health and operational performance in this quarter is crucial for assessing BMY's value.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 1997

Summary

Key Highlights

Frequently Asked Questions